Talk to the Institute
Published mark

INOVIO PHARMACEUTICALS, INC.

NASDAQ: INO. Canonical company identity and public leadership record.

US

Record source reportedRecord not claimedNo Eval published
Follow companySave PDF
Alpha ID
alpha:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65
SEC CIK
0001055726
Record version
vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce, published Oct 17, 2026
Newest evidence
Apr 7, 2026
Monitoring
Not yet monitored Details
Integrity
Not yet signed Methodology
CEO
Jacqueline E. Shea, Ph.D.Since Apr 7, 2026
Chair
Not published
Independent
6 / 88 directors published
Published claims
282 distinct sources
Evidence records
70 pinned
Source conflicts
0None open

Built from 2 distinct sources and 7 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.

CorroboratedSource reportedAlpha inferenceNot disclosed

Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works

CEO CHANGED

Jacqueline E. Shea, Ph.D. executive of INOVIO PHARMACEUTICALS, INC., effective 2026-04-07.

EffectiveEffective Apr 7, 2026E3

Monitoring

Continuous

What the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.

  • Identityunclaimed
    Published
  • Evidencesource_reported
    Published
  • Evaluationnot_evaluated
    Published
  • MonitoringNot yet published for this record.
    Not published
  • AuthorityNot yet published for this record.
    Not published
  • Freshnesscurrent
    Published

Leadership

Evidence
RolePersonSinceStatusClaim
President, Chief Executive Officer and DirectorJacqueline E. Shea, Ph.D.Apr 2026currentSource reportedE3
Chief Scientific OfficerLaurent M. Humeau, Ph.D.Apr 2026currentSource reportedE4
Chief Medical Officer and Head of DevelopmentMichael Sumner, M.D.Apr 2026currentSource reportedE5
Chief Financial OfficerPeter D. KiesApr 2026currentSource reportedE6

Board of directors

Evidence

8 directors published. 6 of 8 with a published determination are independent.

DirectorStatusSinceCommitteesClaim
Ann C. Miller, M.D.Independent2019None publishedSource reportedE2
David B. Weiner, Ph.D.Not independent2016None publishedSource reportedE2
Jacqueline E. Shea, Ph.D.Not independent2022None publishedSource reportedE2
Jay P. ShepardIndependent2020AuditAudit; Nominating and GovernanceNominating and GovernanceSource reportedE2
Lota S. ZothIndependent2019Audit, chairAudit · Chair; CompensationCompensationSource reportedE2
Roger D. Dansey, M.D.Independent2021None publishedSource reportedE2
Simon X. BenitoIndependent2003AuditAudit; Compensation; Nominating and Governance · ChairCompensationNominating and Governance, chairSource reportedE2
Wendy L. YarnoIndependent2017Compensation, chairCompensation · Chair; Nominating and GovernanceNominating and GovernanceSource reportedE2

Committees and risk ownership

Evidence
CommitteeChairMembersRisks assigned
AuditLota S. ZothLota S. Zoth, Jay P. Shepard, Simon X. BenitoNot described in the published record
Audit · Chair; CompensationNot publishedLota S. ZothNot described in the published record
Audit; Compensation; Nominating and Governance · ChairNot publishedSimon X. BenitoNot described in the published record
Audit; Nominating and GovernanceNot publishedJay P. ShepardNot described in the published record
CompensationWendy L. YarnoWendy L. Yarno, Lota S. Zoth, Simon X. BenitoNot described in the published record
Compensation · Chair; Nominating and GovernanceNot publishedWendy L. YarnoNot described in the published record
Nominating and GovernanceSimon X. BenitoSimon X. Benito, Jay P. Shepard, Wendy L. YarnoNot described in the published record
Committee RecordAudit: Chair Lota S. Zoth; Members Lota S. Zoth (Chair); Jay P. Shepard; Simon X. Benito
Source reportedE7
company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65:committee_record:17
Committee AppointmentLota S. Zoth: chair, Audit
Source reportedE7
company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65:committee_appointment:18
Committee AppointmentJay P. Shepard: member, Audit
Source reportedE7
company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65:committee_appointment:19
Committee AppointmentSimon X. Benito: member, Audit
Source reportedE7
company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65:committee_appointment:20
Committee RecordCompensation: Chair Wendy L. Yarno; Members Wendy L. Yarno (Chair); Lota S. Zoth; Simon X. Benito
Source reportedE7
company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65:committee_record:21
Committee AppointmentWendy L. Yarno: chair, Compensation
Source reportedE7
company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65:committee_appointment:22
Committee AppointmentLota S. Zoth: member, Compensation
Source reportedE7
company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65:committee_appointment:23
Committee AppointmentSimon X. Benito: member, Compensation
Source reportedE7
company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65:committee_appointment:24
Committee RecordNominating and Governance: Chair Simon X. Benito; Members Simon X. Benito (Chair); Jay P. Shepard; Wendy L. Yarno
Source reportedE7
company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65:committee_record:25
Committee AppointmentSimon X. Benito: chair, Nominating and Governance
Source reportedE7
company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65:committee_appointment:26
Committee AppointmentJay P. Shepard: member, Nominating and Governance
Source reportedE7
company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65:committee_appointment:27
Committee AppointmentWendy L. Yarno: member, Nominating and Governance
Source reportedE7
company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65:committee_appointment:28

Control and voting power

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Authority to act

Evidence and agent registry

Who can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.

Principal executive officerJacqueline E. Shea, Ph.D., President, Chief Executive Officer and Director, from Apr 7, 2026
Source reportedE3
company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65:leadership_role:13
Who can authorize an agentNot assessedNo Alpha inference about signing authority or board-reserved matters is published for this record.
Not assessed
bind
AI agents registered by the companyNot registered in the public RegistryAgent Deployments, Agent Use Cases, Authority Grants, TrustChecks, Action Ledger entries and Governance Receipts live in the private enterprise overlay. They are never projected into the public Registry without explicit cross-plane authorization. Absence here is a plane boundary, not evidence that the enterprise operates no agents.
Agent registry
agents
Delegations publishedNot disclosedBoard and officer delegation resolutions are not public filings and are not published in this record.
Search scope
delegations

Financials and market context

Evidence
Security ListingINO (NASDAQ)
Source reportedE1
company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65:security_listing:29
Index membershipsNo current membership is published in Alpha's tracked index universe.This is not evidence that the company is absent from every market index.
None publishedAs of Oct 17, 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.

Governance and policies

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Risk, audit, and cyber

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

AI oversight and accountability

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Compensation

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Other published claims

Evidence

Published Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.

Legal NameINOVIO PHARMACEUTICALS, INC.
Source reportedE1
company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65:legal_name:1
Entity StatusPublic listing published
Source reportedE1
company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65:entity_status:3

Not yet in this record

Coverage

A gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.

  • Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
  • OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
  • FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
  • CompensationNot reviewed. Pay design shows how incentives are governed.
  • GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
  • Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
  • AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
  • LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
  • RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
  • CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
  • AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
  • Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
  • Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
  • Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
  • Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
  • Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
  • This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.

Subject and corrections

Public-role doctrine

This record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.

Basis
Published company record built from public sources
Sources
7 evidence records cited. 0 with redistribution rights.
Never published
Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
Record claimed
No
Open disputes
0
Identity ownership
unclaimed
Claiming not yet available

If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.

Evidence

Authority and rights
  1. E1
    Alpha canonical company public projection
    Alpha canonical company public projection. canonical identity. Retrieved Oct 17, 2026. Cited by 4 Claims.
    Open web
    Rights not recorded, link only
    Evidence not pinned
  2. E2
    INOVIO PHARMACEUTICALS, INC. DEF 14A 2026-04-07
    sec proxy. Published Apr 7, 2026. Retrieved Apr 24, 2026. Cited by 8 Claims.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  3. E3
    INO DEF 14A executive officers
    sec filing. Published Apr 7, 2026. Retrieved May 16, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  4. E4
    INO DEF 14A executive officers
    sec filing. Published Apr 7, 2026. Retrieved May 16, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  5. E5
    INO DEF 14A executive officers
    sec filing. Published Apr 7, 2026. Retrieved May 16, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  6. E6
    INO DEF 14A executive officers
    sec filing. Published Apr 7, 2026. Retrieved May 16, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  7. E7
    Audit
    board_seats. board seats. Cited by 12 Claims.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned

What changed in version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce

vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce published Oct 17, 2026
  • Jacqueline E. Shea, Ph.D. executive of INOVIO PHARMACEUTICALS, INC., effective 2026-04-07.
  • Laurent M. Humeau, Ph.D. executive of INOVIO PHARMACEUTICALS, INC., effective 2026-04-07.
  • Michael Sumner, M.D. executive of INOVIO PHARMACEUTICALS, INC., effective 2026-04-07.
  • Peter D. Kies executive of INOVIO PHARMACEUTICALS, INC., effective 2026-04-07.
  • Jacqueline E. Shea, Ph.D. seat on INOVIO PHARMACEUTICALS, INC., effective 2022-01-01.
  • Roger D. Dansey, M.D. seat on INOVIO PHARMACEUTICALS, INC., effective 2021-01-01.
  • Jay P. Shepard seat on INOVIO PHARMACEUTICALS, INC., effective 2020-01-01.
  • Audit; Nominating and Governance committee of INOVIO PHARMACEUTICALS, INC., effective 2020-01-01.
  • Jay P. Shepard member of Audit; Nominating and Governance, effective 2020-01-01.
  • Ann C. Miller, M.D. seat on INOVIO PHARMACEUTICALS, INC., effective 2019-01-01.
  • Lota S. Zoth seat on INOVIO PHARMACEUTICALS, INC., effective 2019-01-01.
  • Audit · Chair; Compensation committee of INOVIO PHARMACEUTICALS, INC., effective 2019-01-01.
  • Lota S. Zoth member of Audit · Chair; Compensation, effective 2019-01-01.
  • Wendy L. Yarno seat on INOVIO PHARMACEUTICALS, INC., effective 2017-01-01.
  • Compensation · Chair; Nominating and Governance committee of INOVIO PHARMACEUTICALS, INC., effective 2017-01-01.
  • Wendy L. Yarno member of Compensation · Chair; Nominating and Governance, effective 2017-01-01.
  • David B. Weiner, Ph.D. seat on INOVIO PHARMACEUTICALS, INC., effective 2016-01-01.
  • Simon X. Benito seat on INOVIO PHARMACEUTICALS, INC., effective 2003-01-01.
  • Audit; Compensation; Nominating and Governance · Chair committee of INOVIO PHARMACEUTICALS, INC., effective 2003-01-01.
  • Simon X. Benito member of Audit; Compensation; Nominating and Governance · Chair, effective 2003-01-01.
Appearance

Alpha Governance PBC. The Registry records reported facts and Alpha's assessments separately. A missing fact is not evidence that it is false.

Record alpha:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65, version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce. https://registry.alpha.ac/companies/inovio-pharmaceuticals-inc

Navigate

On this record

  1. Overview
  2. Monitoring4
  3. Leadership4
  4. Board8
  5. Committees7
  6. Control and voting0
  7. Authority to act4
  8. Financials1
  9. Governance0
  10. Risk0
  11. AI oversight0
  12. Legal0
  13. Compensation0
  14. Other published claims3
  15. Coverage gaps17
  16. Linked people11
  17. Subject and corrections6
  18. Evidence7
  19. Version historyvpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce

Linked records

Registry

Appearance

esc
  • Actions
    Switch to agent viewJSON, Markdown, MCP
  • Copy Alpha IDalpha:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65
  • Cite this recordINOVIO PHARMACEUTICALS, INC.
  • Copy canonical URLregistry.alpha.ac/companies/inovio-pharmaceuticals-inc
  • Copy as MarkdownWith assertion states
  • Report an error
  • Theme: System
  • Theme: Light
  • Theme: Dark
  • Records
    INOVIO PHARMACEUTICALS, INC.Company
  • Jacqueline E. Shea, Ph.D.Person
  • Laurent M. Humeau, Ph.D.Person
  • Michael Sumner, M.D.Person
  • Peter D. KiesPerson
  • Ann C. Miller, M.D.Person
  • David B. Weiner, Ph.D.Person
  • Jay P. ShepardPerson
  • Lota S. ZothPerson
  • Roger D. Dansey, M.D.Person
  • Simon X. BenitoPerson
  • Wendy L. YarnoPerson
  • Sections
    OverviewINOVIO PHARMACEUTICALS, INC.
  • MonitoringINOVIO PHARMACEUTICALS, INC.
  • LeadershipINOVIO PHARMACEUTICALS, INC.
  • BoardINOVIO PHARMACEUTICALS, INC.
  • CommitteesINOVIO PHARMACEUTICALS, INC.
  • Control and votingINOVIO PHARMACEUTICALS, INC.
  • Authority to actINOVIO PHARMACEUTICALS, INC.
  • FinancialsINOVIO PHARMACEUTICALS, INC.
  • GovernanceINOVIO PHARMACEUTICALS, INC.
  • RiskINOVIO PHARMACEUTICALS, INC.
  • AI oversightINOVIO PHARMACEUTICALS, INC.
  • LegalINOVIO PHARMACEUTICALS, INC.
  • CompensationINOVIO PHARMACEUTICALS, INC.
  • Other published claimsINOVIO PHARMACEUTICALS, INC.
  • Coverage gapsINOVIO PHARMACEUTICALS, INC.
  • Linked peopleINOVIO PHARMACEUTICALS, INC.
  • Subject and correctionsINOVIO PHARMACEUTICALS, INC.
  • EvidenceINOVIO PHARMACEUTICALS, INC.
  • Version historyINOVIO PHARMACEUTICALS, INC.
↑ ↓ move↵ openThis record only

Report an error

Reports attach to the Claim and go to an Alpha analyst through the correction form. Corrections are versioned, and the original stays in history.